NCT05151341View on ClinicalTrials.gov

Study of Combined VisioCyt Test and FGFR3 Mutations on a Urinary Sample to Diagnose Bladder Tumors

NACompletedINTERVENTIONAL

Enrollment

190

Participants

Timeline

Start Date

December 13, 2021

Primary Completion Date

December 12, 2024

Study Completion Date

June 12, 2025

Conditions

Bladder Cancer

Interventions

DIAGNOSTIC_TEST

Urine collection (150ml)

Urine collection will be tacken at inclusion. The sample will be thereafter separate into three to realise different analyzes (standard cytology, Visiocyt test, FGFR3 analysis)

OTHER

Blood sample (20 ml)

"Blood sample will be tacken at inclusion, ONLY for case patients that agreed upon this. This sample will be addition to the collection for further research."

Trial Locations (1)

54519

Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy

All Listed Sponsors

collaborator

Vitadx

OTHER

lead

Institut de Cancérologie de Lorraine

OTHER

NCT05151341 - Study of Combined VisioCyt Test and FGFR3 Mutations on a Urinary Sample to Diagnose Bladder Tumors | Biotech Hunter | Biotech Hunter